Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-25

Clinical Trial Update: A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of trastuzumab (Herceptin) as monotherapy for metastatic urothelial cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Urinary Tract Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-09-25